What Is Tesofensine? Structure, Research and Status

Tesofensine is a small-molecule monoamine reuptake inhibitor, not a peptide, that was studied for obesity but is not approved by FDA.

Basics10 min read

Key takeaway

Tesofensine blocks the reuptake of three brain chemical messengers: noradrenaline, dopamine and serotonin. In a 24-week Phase 2 trial in 203 people with obesity, all three tesofensine groups lost more weight than the placebo group. Heart rate rose, and The Lancet later flagged incomplete adverse-event recording in that trial. FDA has not approved tesofensine, and WADA lists it as a stimulant.

At a glance

Article typeBasics
TopicMetabolic & weight
Studies cited10
Related productsIncretin analogs

What is tesofensine is a common question because the compound often appears in discussions of weight-loss research next to peptides. It is a synthetic drug first tested in Parkinson's and Alzheimer's disease. Weight loss seen in those trials led to obesity studies in Denmark and later in Mexico.

Quick answer: Tesofensine is an investigational small-molecule drug with no FDA approval. Its Mexican licensee applied for approval for obesity, and the developer said in May 2026 that the application was still under review.

Vitrapep does not sell tesofensine; this page is a reference summary of published research and regulatory information.

Is tesofensine a peptide?

No. A peptide is a chain of amino acids joined by peptide bonds, as Vitrapep's guide to what peptides are explains. Tesofensine contains no amino acids. PubChem lists its formula as C17H23Cl2NO and its molecular weight as 328.3 g/mol (PubChem).

Its core is a two-ring structure called 8-azabicyclo[3.2.1]octane, the tropane ring system. A dichlorophenyl group and an ethoxymethyl group are attached to that core. PubChem lists the development code NS2330 and the CAS number 195875-84-4.

Like orforglipron, it is a small molecule studied for obesity, but it does not act on the GLP-1 receptor. Table 1 summarizes the key facts.

Table 1

Is tesofensine a peptide

FeatureTesofensineSource
Molecule typeSynthetic small molecule; not a peptidePubChem
Molecular formulaC17H23Cl2NOPubChem
Molecular weight328.3 g/molPubChem
Other namesNS2330, NS 2330; CAS 195875-84-4PubChem
Mechanism studiedBlocks reuptake of noradrenaline, dopamine and serotoninAstrup et al., 2008
Estimated half-life (modelling study)About 234 hours; main metabolite M1 about 374 hoursLehr et al., 2007
Original developerNeuroSearch A/S, DenmarkClinicalTrials.gov
FDA statusNot approved; no Drugs@FDA record foundDrugs@FDA search, Nov 18, 2026
WADA 2026 statusNamed specified stimulant (S6.B), prohibited in competitionWADA, 2025

Where did tesofensine come from?

The Danish company NeuroSearch A/S developed tesofensine and sponsored its first obesity trial (NCT00394667). Before that, Boehringer Ingelheim sponsored Phase 2 trials in Parkinson's disease (NCT00148512, NCT00148486) and Alzheimer's disease (NCT00153010).

Those trials did not show a clear benefit. In early Parkinson's disease, a 14-week trial in 261 people found no significant improvement over placebo (Hauser et al., 2007). In advanced Parkinson's disease, the ADVANS trial found modest improvements in single dose groups but no clear dose-response pattern (Rascol et al., 2008). A 14-week Alzheimer's trial in 430 patients was negative, according to a later modelling paper (Lehr et al., 2010).

Weight loss was the unexpected signal. A pooled analysis of four of those 14-week trials included 740 people on tesofensine and 228 on placebo. Weight rose 0.5% with placebo and fell 0.5% to 2.8% with tesofensine, more at higher doses. The authors wrote that tesofensine was now being developed for obesity (Astrup et al., 2008, Obesity).

Saniona now lists tesofensine in its pipeline. Its May 2026 interim report says Medix holds tesofensine rights for obesity in Mexico and Argentina (Saniona, 2026).

How does tesofensine act in the body?

Nerve cells clear chemical messengers such as dopamine from the gap between cells using transporter proteins. Tesofensine inhibits the presynaptic reuptake of noradrenaline, dopamine and serotonin (Astrup et al., 2008, Lancet).

A brain-imaging study in young men used positron emission tomography (PET) to measure binding to the dopamine transporter. Mean occupancy in the striatum rose with dose, from 18% to 77%. The authors estimated a maximum achievable occupancy of about 80% (Appel et al., 2014). A 2025 structural study found that tesofensine holds the dopamine transporter in an outward-facing shape (Li et al., 2025).

A model built from plasma data in 320 Alzheimer's patients estimated a half-life of 234 hours, or nearly 10 days. Its major metabolite, M1, had an estimated half-life of 374 hours (Lehr et al., 2007).

In people, the clearest measured effect was on appetite. A two-week randomized trial in 32 men with overweight or moderate obesity found higher satiety and fullness ratings than placebo. Total 24-hour energy expenditure did not differ significantly. Night-time energy expenditure was 4.6% higher after adjustment (Sjödin et al., 2010). In a longer trial, a satiety score rose by week 12, then faded as weight loss progressed (Gilbert et al., 2012).

Animal studies help explain the heart rate findings. In rats fitted with telemetry monitors, tesofensine reduced food intake and raised heart rate and blood pressure. Adding metoprolol, a beta-blocker, prevented the cardiovascular effects while food intake stayed suppressed (Bentzen et al., 2013). That finding underlies Tesomet, a tesofensine and metoprolol combination later tested in people.

What did the obesity trials show?

The main published obesity trial enrolled 203 people with a body mass index of 30 to 40 at five Danish centres. All followed an energy-restricted diet. Of the participants, 161 (79%) completed 24 weeks. All three dose groups lost significantly more weight than placebo. The authors said the findings needed confirmation in Phase 3 trials (Astrup et al., 2008, Lancet).

Table 2

What did the obesity trials show

StudyDesignPopulation and sizeDurationMain reported result
Astrup et al., 2008, LancetPhase 2; randomized, double-blind, placebo-controlled; three dose groups; diet in all arms203 people with obesity, five Danish centres24 weeksWeight loss 4.5% to 10.6% across dose groups, versus 2.0% with placebo
Astrup et al., 2008, ObesityPooled analysis of four randomized neurology trials; no weight program968 people with Parkinson's or Alzheimer's disease14 weeksWeight loss 0.5% to 2.8% across dose groups, versus 0.5% gain with placebo
Sjödin et al., 2010Randomized, placebo-controlled; participants kept habitual diet32 men with overweight or moderate obesity2 weeks1.8 kg more weight loss than placebo; higher satiety
Huynh et al., 2022Randomized, placebo-controlled; Tesomet; safety as primary endpoint21 adults with hypothalamic obesity24 weeks6.3% more weight loss than placebo
NCT02737891Phase 2; randomized, double-blind, placebo-controlled; Tesomet60 adults with type 2 diabetes, Germany90 days24-hour mean heart rate 3.8 beats per minute lower than placebo; HbA1c not different

In the hypothalamic obesity trial, 8 of 13 on Tesomet lost at least 5% of body weight, versus 1 of 8 on placebo. In the type 2 diabetes trial, weight fell 3.5 kg more than with placebo. A Prader-Willi syndrome trial in 18 participants found no statistically significant adult weight difference (NCT03149445).

Medix ran a Phase 3 program in Mexico. Saniona says it involved 372 patients over 24 weeks (Saniona, 2024). We found no peer-reviewed publication in PubMed and no ClinicalTrials.gov registration as of November 18, 2026, so its results cannot be checked independently. See how to evaluate peptide research.

Why did The Lancet flag the main obesity trial?

In April 2013, The Lancet published an expression of concern about the 2008 obesity trial (The Lancet, 2013). It followed a Danish Health and Medicines Authority inspection that raised concerns about two of the five sites. According to the notice, the contract research organisation's recording and assessment of adverse events was incomplete. Headache, migraine, stress and depression were not reliably recorded. The notice said the published side-effect profile was not in accordance with the actual course of the trial.

The authors replied in a July 2013 letter (Astrup et al., 2013). An expression of concern is a warning to readers, not a retraction, and PubMed listed no retraction as of November 18, 2026.

What side effects were reported in tesofensine studies?

In the 2008 obesity trial, the most common adverse events caused by tesofensine were dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia. Heart rate rose by 7.4 beats per minute in the middle dose group at 24 weeks. The abstract reports no significant blood pressure rise in the two lower dose groups (Astrup et al., 2008, Lancet). Given the 2013 notice, this published list may be incomplete.

In the pooled neurology analysis, heart rate rose with dose, by up to 6.8 beats per minute, without a blood pressure effect (Astrup et al., 2008, Obesity). In early Parkinson's disease, constipation, insomnia and dry mouth were most common (Hauser et al., 2007). In the ADVANS trial, gastrointestinal and neuropsychiatric events were more frequent than with placebo, especially at higher doses (Rascol et al., 2008).

In the hypothalamic obesity trial, sleep disturbances affected 50% on Tesomet versus 13% on placebo. Dry mouth affected 43% versus none, and headache 36% versus none. One participant stopped because of a treatment-related serious worsening of existing anxiety (Huynh et al., 2022).

In the Prader-Willi syndrome trial, three of six adults in the higher Tesomet group had serious events, recorded as anger, hallucination and abnormal behaviour (NCT03149445). Groups this small cannot give reliable rates.

A single-dose crossover study in recreational stimulant users found subjective effects no different from placebo and lower than D-amphetamine. The authors concluded its abuse potential was no greater than that of bupropion or atomoxetine (Schoedel et al., 2010).

What is tesofensine's regulatory and anti-doping status?

FDA has not approved tesofensine. A search of Drugs@FDA records through openFDA on November 18, 2026 found no tesofensine product.

In a December 8, 2025 warning letter to a Florida distributor of bulk drug ingredients, FDA listed tesofensine among substances "ineligible for use in human drug compounding" under section 503A. FDA said the labeling of these ingredients lacked adequate directions for use, so they were misbranded (FDA, 2025). Vitrapep's guide to 503A and 503B compounding explains that framework.

The 2026 WADA Prohibited List names tesofensine under S6.B, specified stimulants, which are prohibited in competition (WADA, 2025). A 2026 anti-doping study noted that it has been marketed online as a dietary supplement (Krug et al., 2026). Vitrapep's WADA list overview covers the peptide classes.

The only marketing application we found reported is in Mexico. In February 2023, a COFEPRIS technical committee gave a favorable opinion that Saniona said "does not represent a market authorization or rejection" (Saniona, 2023). On November 6, 2024, Saniona said Medix had not received approval (Saniona, 2024).

In February 2025, Medix expected to resubmit its dossier (Saniona, 2025). Saniona's May 2026 report said the application was under review. We found no approval announcement through November 18, 2026.

Two US Tesomet Phase 2 trials were withdrawn before enrollment for financial reasons (NCT05147415, NCT05198362). A research-use label on any product does not make it an approved medicine or legal for people. See research peptides and human-use risks.

How does tesofensine relate to other weight-research compounds?

Tesofensine acts on brain transporters, while GLP-1 medicines mimic a gut hormone, as described in what is GLP-1. No published trial has compared tesofensine directly with an approved obesity medicine. Separate trials cannot be ranked, because populations, diets and durations differ. For registered studies, see how to find a peptide clinical trial.

Frequently asked questions

Is tesofensine a peptide?

No. It is a synthetic small molecule with the formula C17H23Cl2NO and a molecular weight of 328.3 g/mol. It contains no amino acids.

Is tesofensine FDA-approved?

No. We found no tesofensine product in Drugs@FDA. In a December 2025 warning letter, FDA called it ineligible for use in 503A human drug compounding.

Is tesofensine approved in Mexico?

Not as of November 18, 2026. Saniona said in May 2026 that the Mexican application was under review.

What is Tesomet?

Tesomet is a combination of tesofensine and metoprolol, a beta-blocker. It was tested in small Phase 2 trials in hypothalamic obesity, Prader-Willi syndrome and type 2 diabetes.

Is tesofensine banned in sport?

Yes, in competition. The 2026 WADA Prohibited List names tesofensine as a specified stimulant under S6.B.

What side effects were reported in tesofensine trials?

Trials reported dry mouth, nausea, constipation, diarrhoea, insomnia and raised heart rate. Small Tesomet trials also recorded psychiatric events.

What to know now

  • Tesofensine is a small-molecule inhibitor of noradrenaline, dopamine and serotonin reuptake, not a peptide.
  • A 24-week Phase 2 trial in 203 people with obesity found more weight loss than placebo, with raised heart rate.
  • The Lancet issued an expression of concern in 2013 about incomplete adverse-event recording in that trial.
  • FDA has not approved tesofensine, WADA lists it as a stimulant, and Mexico has not approved it.

What we’re watching

  • A COFEPRIS decision on the Medix application for obesity in Mexico.
  • Peer-reviewed publication of the Mexican Phase 3 program, including full adverse-event data.
  • Any new trial registrations for tesofensine or Tesomet on ClinicalTrials.gov.
  • Further FDA enforcement actions that name tesofensine.

Also in the library

Sources: National Center for Biotechnology Information 2026; Astrup 2008, Lancet, 372; The Lancet 2013, Lancet, 381; Astrup 2008, Obesity, 16; Sjödin 2010, International Journal of Obesity, 34; Rascol 2008, Archives of Neurology, 65; Huynh 2022, European Journal of Endocrinology, 186; Appel 2014, European Neuropsychopharmacology, 24; Lehr 2007, British Journal of Clinical Pharmacology, 64; Schoedel 2010, Clinical Pharmacology & Therapeutics, 88; Bentzen 2013, Obesity, 21; U.S. Food and Drug Administration 2025; World Anti-Doping Agency 2025; Saniona AB 2024. All 14 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 11370864, tesofensine. https://pubchem.ncbi.nlm.nih.gov/compound/11370864
  2. Astrup, A., Madsbad, S., Breum, L., Jensen, T. J., Kroustrup, J. P., & Larsen, T. M. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: A randomised, double-blind, placebo-controlled trial. Lancet, 372(9653), 1906-1913. https://pubmed.ncbi.nlm.nih.gov/18950853/
  3. The Lancet. (2013). Expression of concern: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: A randomised, double-blind, placebo-controlled trial. Lancet, 381(9873), 1167. https://pubmed.ncbi.nlm.nih.gov/23561987/
  4. Astrup, A., Meier, D. H., Mikkelsen, B. O., Villumsen, J. S., & Larsen, T. M. (2008). Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity, 16(6), 1363-1369. https://pubmed.ncbi.nlm.nih.gov/18356831/
  5. Sjödin, A., Gasteyger, C., Nielsen, A. L., Raben, A., Mikkelsen, J. D., Jensen, J. K., et al. (2010). The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. International Journal of Obesity, 34(11), 1634-1643. https://pubmed.ncbi.nlm.nih.gov/20479765/
  6. Rascol, O., Poewe, W., Lees, A., Aristin, M., Salin, L., Juhel, N., et al. (2008). Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: The ADVANS study. Archives of Neurology, 65(5), 577-583. https://pubmed.ncbi.nlm.nih.gov/18474731/
  7. Huynh, K., Klose, M., Krogsgaard, K., Drejer, J., Byberg, S., Madsbad, S., et al. (2022). Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. European Journal of Endocrinology, 186(6), 687-700. https://pubmed.ncbi.nlm.nih.gov/35294397/
  8. Appel, L., Bergström, M., Buus Lassen, J., & Långström, B. (2014). Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET. European Neuropsychopharmacology, 24(2), 251-261. https://pubmed.ncbi.nlm.nih.gov/24239329/
  9. Lehr, T., Staab, A., Tillmann, C., Trommeshauser, D., Raschig, A., Schaefer, H. G., & Kloft, C. (2007). Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. British Journal of Clinical Pharmacology, 64(1), 36-48. https://pubmed.ncbi.nlm.nih.gov/17324246/
  10. Schoedel, K. A., Meier, D., Chakraborty, B., Manniche, P. M., & Sellers, E. M. (2010). Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clinical Pharmacology & Therapeutics, 88(1), 69-78. https://pubmed.ncbi.nlm.nih.gov/20520602/
  11. Bentzen, B. H., Grunnet, M., Hyveled-Nielsen, L., Sundgreen, C., Lassen, J. B., & Hansen, H. H. (2013). Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity, 21(5), 985-992. https://pubmed.ncbi.nlm.nih.gov/23784901/
  12. U.S. Food and Drug Administration. (2025, December 8). Warning letter 320-26-24 (MARCS-CMS 716152). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025
  13. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  14. Saniona AB. (2024, November 6). Mexican application for tesofensine not yet approved [Press release]. https://mfn.se/a/saniona/mexican-application-for-tesofensine-not-yet-approved